Neoplastic diseases are frequently associated with metabolic changes collectively known as cancer cachexia. The presence of cachexia complicates therapeutic intervention and is an important cause of death in cancer patients. At present there is no effective treatment for cachexia. Recently, the involvement of interleukin-6 (IL-6) in the wasting of colon-26 adenocarcinoma-bearing mice was demonstrated. The research presented here establishes an anticachectic role for the experimental drug suramin, since it partially blocks (up to 60%) the catabolic effects associated with the growth of this tumor in vivo. Suramin prevents the binding of IL-6 to its cell surface receptor subunits, as demonstrated by radioreceptor binding assay and affinity crosslinking experiments. Furthermore, the uptake of radioactive IL-6 by the liver is significantly reduced in suramintreated mice. On the other hand, the drug is 10-fold less potent in inhibiting the binding of tumor necrosis factor-a to indicator cell line in vitro and fails to block liver uptake of this cytokine in vivo. Collectively, these results suggest that suramin inhibits cancer-associated wasting, in part by interfering with the binding of IL-6 to its receptor. Whether suramin inhibits the action ofother factors /cytokines that may also participate in colon-26-mediated cachexia is not yet known. (J. Clin.
Introduction
Weight loss is a common manifestation of many chronic illnesses, including cancer, and bacterial, viral, and parasitic infections ( 1) . In humans, neoplastic diseases are frequently associated with a constellation of metabolic changes collectively known as "cancer cachexia" (2, 3) . Among these changes are progressive wasting of both muscle and fat tissues, anemia, anorexia, and asthenia. Cachexia long has been recognized as an important cause of death in cancer patients (4) , and patients who exhibit cachexia have a reduced response to chemotherapy (5) . Wasting is common in cancer patients. Up to 50% of all patients have lost weight by the time of diagnosis, and nearly all patients who die from cancer exhibit wasting (6) . Recent attempts to compensate, through total parenteral nutrition, for the negative caloric balance in patients failed to alter wasting (7) . The mitigation of wasting by pharmacological intervention, therefore, is important not only because anticachexia therapy could improve the survival and quality oflife of the patient, but also because it could give way to a more effective anticancer therapy.
Cachectin/TNF has been suggested as an important mediator of cancer cachexia because it suppresses key metabolic enzymes and induces anorexia and weight loss in animals ( 1, (8) (9) (10) . Recently, however, an experimental cachexia model has been identified that appears to involve another cytokine. The model uses a cell line derived from colon-26 adenocarcinoma (C-26),' which retains the transplantability ofthe original tumor in syngeneic mice and fulfills the criteria ofearly-onset wasting without apparent anorexia ( 11) . In at least this model, IL-6 appears to have a more significant role than TNF in mediating the myriad parameters ofcachexia ( 11 ) . The cellular source of this model is believed to be derived from the tumor cells, in response to IL-1 provided by tumor-infiltrating mononuclear phagocytes ( 12) .
The experimental drug suramin (a polysulfated naphthylurea) was originally developed as an antitrypanosomal and antifilarial agent ( 13 ) . Recently suramin was found to inhibit the growth ofseveral tumor cell lines in culture ( 14, 15) , and to inhibit the enzyme reverse transcriptase ( 16) . Previous work suggested that suramin blocks the activity of IL-6 as an autocrine/paracrine growth factor in human multiple myeloma cell lines ( 17, 18) . Suramin can also induce cell differentiation in several systems ( 19) , suppress tumor cell invasion (20) , and inhibit the nuclear enzyme DNA topoisomerase 11(21 ) . Therefore, suramin is currently being investigated in the clinic for the treatment of AIDS (22) and several inoperable cancers (23, 24) . In culture, suramin is known to block binding of various growth factors (among them EGF, IGF-1, TGF-#l, PDGF, and basic fibroblast growth factor) to their corresponding cell surface receptors (25) (26) (27) (28) (29) . In this report, we demonstrate that suramin interferes with the binding of IL-6 to its cell surface receptor, and significantly inhibits the catabolism of C-26-bearing hosts.
Mice. Virus-free, male BALB/c X DBA/2 (CD)F, mice were purchased from Charles River Breeding Laboratories (Wilmington, MA). Mice were housed under conventional conditions and were used at 8-14 wk of age.
Radioactive IL-6. Human '25I-IL-6 (sp act, 2,000 Ci/mmol) was purchased from Amersham Corp. (Arlington Heights, IL) or was labeled by us. Briefly, IL-6 (R & D Systems, Minneapolis, MN) was labeled using the diiodo 1251I-Bolton-Hunter reagent (2, 200 Ci/mmol; DuPont/NEN, Boston, MA) as previously described (30) . The specific activity of the '251I-IL-6 was calculated to be 2-4 x 1015 cpm/ mmol. More than 99% of the radioactivity corresponded to a single band of IL-6 when analyzed under both reducing and nonreducing SDS-PAGE, and autoradiography. Human '251-TNFa (sp act, 520 Ci/ mmol) was purchased from New England Nuclear (Boston, MA). The biologic activity of the radioactive IL-6 was found to be essentially unchanged as measured using the,IL-6-dependent B-9 cell line.
Affinity crosslinking of'25I-IL-6 to its receptor. Affinity crosslinking was performed using a modification of a previously published procedure (31) . Briefly, cells were washed twice and resuspended at 5 x I0' cells/ml in cold binding medium (RPMI 1640,0.05% sodium azide). Binding was allowed to proceed on ice for the indicated time with the indicated amount of 1251I-IL-6. After binding, the cells were washed with cold RPMI 1640/0.05% sodium azide to remove the unbound 1251I-IL-6
and resuspended in 1 ml of PBS, 1 mM MgCl2, pH 8.3. Crosslinking was initiated by the addition of 300 gg/ml disuccinimidyl suberate (Pierce Chemical Co., Rockford, IL), as indicated, and allowed to proceed at 40C for 15 min. The crosslinking reaction was stopped by centrifugation and by immediate lysis of the cells with 50 mM Tris-HCl, 300 mM NaCl, 1% NP-40, 1 mM PMSF, 10 mM leupeptin, and 10 mM pepstatin, pH 7.5 (lysis buffer), for 30 min on ice. The lysate was centrifuged for 10 min at 15,000 g and the supernatant collected for analysis by SDS-PAGE and autoradiography.
Binding assays. This assay was performed as described previously (32) . U-266 cells were grown to confluence, medium was removed, and the cells were washed in binding buffer (RPMI 1640 supplemented with 0.1 mg/ml BSA and 25 mM Hepes, pH 7.2), and 0.05-ml aliquots of 10 x 106 cells/ml were dispensed into tubes on ice. Increasing amounts of suramin and 0.8 ng of '25I-IL-6 were added simultaneously at the indicated concentrations. The cells were incubated for 90 min at 4°C with gentle agitation. To separate cells bound from free 1251I-IL-6, 0.2 ml of an oil mixture was injected into the bottom of the tubes, which were centrifuged for 1 min. The fluid was aspirated, the tube tips were cut, and cell-bound radioactivity was determined in a gamma counter. Binding of 12'I-TNFa (1.0 ng) was performed on confluent monolayers of MCF-7 cells with the same binding buffer. Cells were then washed three times with cold binding buffer, trypsinized, and cell-bound radioactivity was measured.
IL-6 bioassay and ELISA. This assay was previously described (32) . Briefly, B-9 cells were grown in human IL-6. To measure IL-6 activity in serum or inhibition by suramin, IL-6-dependent B-9 cells (5 x 103/well) were cultured at a final volume of 0.2 ml with or without diluted samples in flat-bottomed 96-well plates (Falcon Labware, Oxnard, CA). After incubation for 72 h, cells were pulsed for the final 4 h with 1 MCi/well of [3H]thymidine. Incorporation of radioactivity was determined by standard liquid scintillation counting procedures after collection of cells on glass fiber paper. Results are expressed in units where 1 U was defined as the reciprocal dilution required for half-maximal stimulation of the cells. IL-6 was also quantified by a murine-specific IL-6 ELISA (Endogen, Boston, MA).
Measurement ofcachexia markers. Mice were inoculated with 0.5 X 106 C-26.IVX cells subcutaneously to the right flank as described (11, 12) . Treatments were performed as indicated in the tables. Mice were weighed between 9 and 11 a.m. several times per week. The length and width of their tumors were measured using an engineering caliper, and estimation of tumor weight was calculated, as previously described, for the same tumor (33) . Significant weight loss in C-26-bearing mice occurred between 12 and 14 d after tumor inoculation. Host weight was calculated by subtracting tumor weight (obtained by resection) from total weight. Blood was obtained by cardiac puncture (-0.8 ml), and serum was harvested after the clotting of blood at room temperature for 1 h. Serum was kept frozen (-45°C) until analysis. Measurements of serum glucose were performed using an Ektachem DT-60 analyzer (Eastman Kodak Co., Rochester, NY). Dry weight was determined (after removal of the tumor, blood, and right epididymal fat pad) by oven drying for 3 d at 85°C. The neutralizing mAb against murine IL-6 20F3 was the gift of Dr. C. 0. Jacob (Syntex Research, Palo Alto, CA) (11) .
Statistical analysis. Results throughout the paper are presented as mean±SD. Differences in cachexia markers were calculated using computerized analysis of variance (ANOVA).
Results
Inhibition ofIL-6 activities by suramin in vitro. The addition of suramin to the B-9 murine myeloma line inhibits the proliferation ofthese cells in response to IL-6. Half-maximal inhibition of thymidine incorporation was seen at -30 MM of the drug when various doses (3-30 pg/ ml) of recombinant human (rh) IL-6 were added to the culture (Table I ). In contrast, 10-fold more drug was required to achieve the same extent of inhibition when B-9 cells were incubated with 1 ng/ml of IL-6 (not shown). The inhibition was not specific to IL-6, since the drug also inhibited B-9 proliferation in response to increasing concentrations of IL-4. When B-9 cells were pretreated with suramin, up to 1 mM for 1 h at room temperature, followed by (25) (26) (27) (28) , it was of interest to determine whether the inhibition of B-9 cell growth was possibly due to the prevention of IL-6 binding to its receptor. To this end, the U-266 human myeloma line, which expresses a relatively high number of IL-6 receptors, was used in standard IL-6 receptor binding assays. At 4VC, suramin inhibited the binding of 1251-IL-6 to U-266 cells (Fig. 1) . In this representative experiment, the extent ofinhibition ofcell-associated radioactivity reached almost 100%. The determination ofbackground binding involved the addition of625-fold excess of cold IL-6. This experiment was highly reproducible, since more than eight experiments in two separate laboratories with different batches of radioactive IL-6 showed similar results. Half-maximal inhibition in these experiments was achieved at 30 ,uMof the drug. On the other hand, suramin was not as effective in inhibiting the binding of 1251-TNFa to the MCF-7 cell line. Half-maximal inhibition of TNFa binding was achieved at only -300 gM of the drug (Fig. 1) . To analyze still further the inhibitory effect of suramin on IL-6 binding, affinity crosslinking experiments were performed. Crosslinking membrane-bound '251-IL-6 to U-266 cells generates three IL-6-containing crosslinked complexes with molecular masses of 100, 120, and 150 kD. As shown in Fig. 2 , suramin concentrations as low as 25 MM display inhibition of complex formation whereas concentrations 2 100 M completely block the formation of all three IL-6/IL-6 receptor complexes. To better understand this effect, we asked if suramin could dissociate bound IL-6 from the receptor complex. Fig. 3 demonstrates that concentrations of suramin that inhibit the formation of IL-6/IL-6 receptor complexes are unable to dissociate bound IL-6 from the receptor complex. In addition, radioreceptor binding assays confirmed the results presented in Fig. 3 . At 4VC, suramin did not displace prebound radioactive IL-6 on U-266 cells (not shown). Suramin inhibits C-26-mediated wasting. The administration of suramin to C-26.IVX-bearing mice on days 7 and 12 significantly improved the total weight (host and tumor) of a ' ! + these animals as compared with PBS-injected controls (Fig. 4 A). The measurements of tumor volume in the experiment revealed that, on days 14 and 17 ofposttumor inoculation, the suramin-treated hosts were significantly protected from wasting, since they exhibited an identical tumor burden to controltreated hosts (Fig. 4 B) . On day 19, suramin-treated animals showed a statistically larger tumor burden. However, for unknown reasons, this augmentation in tumor burden did not occur in all the experiments (for example, see Table II min significantly inhibited (P < 0.01 from control-treated mice) C-26-mediated wasting (Fig. 6) . However, the coadministration ofboth the 20F3 antibody and suramin did not add to re with IL-6 binding in vivo. Table III illustrates the the protection against wasting provided by suramin alone. One of suramin to significantly reduce the sequestration of possible interpretation for this lack ofadditivity is that suramin 6 to the livers of normal CDF1 mice. In contrast, sura-inhibits wasting by interfering with the action of IL-6 in vivo. min increased the radioactivity associated with the kidney (Table III), but did not change the level of radioactivity in the blood (not shown). Under the same conditions in a subsequent experiment, suramin inhibited '25I-IL-6 binding to the liver by 48% and significantly increased radioactivity present in the urine (111,833±3,590 cpm in 0.1 ml urine from suramin-injected mice vs. 45,251 + 10,568 cpm in 0.1 ml urine from PBSinjected mice, measured 1 h after radioactive IL-6 injection). This increase in urine radioactivity suggests that suramin may accelerate the clearance ofIL-6 in vivo. Ofnote, the administration of 15 ,gg ofunlabeled IL-6, together with 1.2 ng of 251-IL-6, failed to reduce the liver-associated radioactivity (not shown). Therefore, the background binding of 1251-IL-6 in the assay shown in Table III 
Discussion
Previous observations in myeloma cells that suramin inhibits IL-6-stimulated growth and immunoglobulin secretion (17, 18) suggested that suramin could also interfere with experimental cancer cachexia where IL-6 was shown to be involved ( 11) .
We demonstrate here for the first time the capacity ofa chemical (i.e., suramin) to interfere with the binding ofIL-6 to its cell surface receptor and to have a significant beneficial effect on reducing cancer-associated weight loss.
In a dose-dependent fashion, suramin inhibits the proliferation of B-9 cells (a standard IL-6 bioassay) in response to IL-6. The ability of the drug to inhibit IL-6-dependent growth is not restricted to this cytokine, since suramin inhibits the proliferation of the same indicator cells to IL-4 ( Table I ). The findings Normal CDF1 mice were injected intravenously with PBS (0.2 ml) or with suramin (5 mg), 20 min before intravenous administrations of 125I-I.6 (300,000 cpm; -1.2 ng). At the indicated time points (relative to the injection of '25-IL-6), mice were killed and organs were removed and counted. Results are expressed as cpm±SD of four mice. Liver radioactivity is expressed as cpm/g tissue. The numbers in parentheses indicate percent of injected cpm. that the extent of inhibition had an inverse relation to the amount of IL-6 and, second, that the inhibitory effect of the compound could be removed in pretreatment experiments (up to 1 mM, for 1 h; data not shown), suggest that the effect of suramin on B-9 cells is reversible. Radioreceptor assays conducted at 4°C showed that suramin inhibited the binding of radioactive IL-6 to U-266 human myeloma in a dose-dependent manner (Fig. 1 ) . It is interesting to note that suramin was found to be 10-fold less potent in inhibiting the binding of TNFa to the MCF-7 human breast cancer line. More direct evidence for the interference of IL-6 receptor binding by suramin comes from crosslinking studies. As previously reported, crosslinking membrane-bound '251I-IL-6 to U-266 cells generates three IL-6-containing crosslinked complexes with molecular masses of 100, 120, and 150 kD (35) . The 100-and 120-kD complexes represent one and two molecules, respectively, of IL-6(20 kD) crosslinked to an 80-kD membrane protein, whereas the 1 50-kD complex consists of IL-6 crosslinked to a 130-kD membrane protein. (Figs. 4 and 5) . Specifically, two administrations of suramin at doses of > 75 mg/kg prevented, by -60%, the loss of precachectic weight of C-26-bearing hosts. Body compositional analysis revealed that suramin inhibited the wasting of both muscle and fat tissues, and reduced the extent of hypoglycemia (Table II) . Because suramin did not prevent C-26-mediated weight loss completely, it is possible that IL-6 is but one of several factors influencing host catabolism in the C-26 cachexia model. These still undetermined factors might be suramin insensitive. One such suramin-insensitive factor may be the competition between progressing C-26 tumors and the host for essential nutrients, a phenomenon known to occur in experimental cachexia (38) . The beneficial effect of suramin on weight loss is not due to added nutritional value, since the drug is known to be poorly metabolized (22) .
Suramin treatment did not result in a decrease of tumor burden at the same time as it protected weight loss. This suggests that the drug affects the host directly. In some experiments, a small but significant augmentation of tumor size was seen in suramin-treated mice. However, this phenomenon occurred at a time when suramin-treated mice were protected from weight loss, while control-treated animals exhibited significant wasting. In addition, when a given dose of the drug was administered over a 5-d period, rather than injected twice, the increase in tumor burden disappeared (Table II) . Moreover, suramin neither inhibited nor augmented the growth of C-26.IVX (data not shown), in contrast to its ability to prevent the proliferation of several other cancer lines in culture ( 14, 15) . Taken together, this information establishes a role for suramin as an anticachectic agent, in addition to its known antineoplastic effect. It remains to be established whether suramin prevents wasting associated with the growth of other tumors in vivo.
Suramin inhibits IL-6 activities in vitro and suppresses catabolism of C-26-bearing mice, where IL-6 plays a role in mediating cachexia ( 11) (Fig. 6 ). In addition to IL-6, suramin also prevents the binding of IL-l to type I and II IL-l receptors (G. Strassmann, unpublished results). IL-1 has been shown to upregulate IL-6 production by the C-26 tumor in vitro ( 12) , and intratumoral, but not systemic, administration of IL-l receptor antagonist inhibits C-26-mediated wasting (39) . Since suramin treatment increases IL-6 levels in the circulation of C-26-bearing mice, it is not likely that inhibition of cachexia in vivo is due to tumor IL-1 receptor blockade. It is still possible, however, that suramin inhibits the action ofother factors that, together with IL-6, may influence C-26-mediated cachexia. IL-6 is a multifunctional cytokine. In addition to its involvement in cancer cachexia, it has been implicated in the pathophysiology ofrheumatoid arthritis, Kaposi sarcoma, B cell malignancies, Castleman's disease, cardiac myxoma (39) , and Alzheimer syndrome (40) . Ultimately, then, the identification of suramin as an inhibitor of IL-6 may lead to the discovery of other chemicals capable of exerting even more potent and specific antagonism to this pleiotropic cytokine.
